THE ROLE OF CHRONIC HEPATITIS C VIRUS IN THE DEVELOPMENT OF LIVER CIRRHOSIS AND CLINICAL OUTCOMES

Authors

Kaxarov Abdukaxar Nabijonovich Assistant Department of infectious diseases, Andijan State Medical Institute, Uzbekistan, Andijan

Keywords:

Hepatitis C Virus, Liver Cirrhosis, Chronic Hepatitis, Hepatocellular Carcinoma, Direct-Acting Antivirals, Liver Fibrosis, Portal Hypertension, Disease Progression.

Abstract

Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver disease worldwide, culminating in significant morbidity and mortality. The progression from chronic hepatitis to cirrhosis is a complex, multifactorial process that represents a critical turning point in the natural history of the disease. This article provides a comprehensive review of the pivotal role of HCV in the pathogenesis of liver cirrhosis, detailing the virological and host factors that influence disease progression. We explore the clinical manifestations and diverse outcomes of HCV-related cirrhosis, including the development of decompensated liver disease, hepatocellular carcinoma (HCC), and extrahepatic manifestations. Furthermore, we discuss the diagnostic modalities, management strategies, and the transformative impact of direct-acting antiviral (DAA) therapy on preventing cirrhosis and improving patient outcomes. Despite the success of DAAs, challenges remain in managing patients with pre-existing advanced fibrosis or cirrhosis, highlighting the continued importance of understanding the long-term sequelae of this infection. This review synthesizes current knowledge to provide a detailed perspective on the clinical challenges and management of HCV-induced cirrhosis.

Downloads

Download data is not yet available.

References

(Formatted in APA 7th Edition style. Note: Hyperlinks are provided where available through DOIs.)

World Health Organization. (2023). Hepatitis C. WHO. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

Liang, T. J., & Ghany, M. G. (2013). Current and future therapies for hepatitis C virus infection. New England Journal of Medicine, 368(20), 1907–1917. https://doi.org/10.1056/NEJMra1213651

Thein, H. H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008). Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology, 48(2), 418–431. https://doi.org/10.1002/hep.22375

Poynard, T., Bedossa, P., & Opolon, P. (1997). Natural history of liver fibrosis progression in patients with chronic hepatitis C. The Lancet, 349(9055), 825–832. https://doi.org/10.1016/S0140-6736(96)07642-8

Friedman, S. L. (2008). Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiological Reviews, 88(1), 125–172. https://doi.org/10.1152/physrev.00013.2007

Bochud, P. Y., Cai, T., Overbeck, K., Eijsink, R., Bibert, S., Lagging, M., ... & Negro, F. (2009). Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of Hepatology, 51(4), 655–666. https://doi.org/10.1016/j.jhep.2009.05.016

van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J. F., Lammert, F., ... & Janssen, H. L. (2012). Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 308(24), 2584–2593. https://doi.org/10.1001/jama.2012.144878

Morgan, R. L., Baack, B., Smith, B. D., Yartel, A., Pitasi, M., & Falck-Ytter, Y. (2013). Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Annals of Internal Medicine, 158(5_Part_1), 329–337. https://doi.org/10.7326/0003-4819-158-5-201303050-00005

D'Ambrosio, R., Aghemo, A., Rumi, M. G., Ronchi, G., Donato, M. F., Paradis, V., ... & Colombo, M. (2012). A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus-related cirrhosis. Hepatology, 56(2), 532–543. https://doi.org/10.1002/hep.25606

Ioannou, G. N., Green, P. K., & Berry, K. (2017). HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. Journal of Hepatology, 68(1), 25-32. https://doi.org/10.1016/j.jhep.2017.08.030

European Association for the Study of the Liver. (2018). EASL Recommendations on Treatment of Hepatitis C 2018. Journal of Hepatology, 69(2), 461–511. https://doi.org/10.1016/j.jhep.2018.03.026

Singal, A. G., & El-Serag, H. B. (2015). Hepatocellular carcinoma from epidemiology to prevention: a complex puzzle. Clinical Liver Disease, 20(4), 1-13. https://doi.org/10.1002/cld.508

Downloads

Published

2025-10-20

How to Cite

Kaxarov Abdukaxar Nabijonovich. (2025). THE ROLE OF CHRONIC HEPATITIS C VIRUS IN THE DEVELOPMENT OF LIVER CIRRHOSIS AND CLINICAL OUTCOMES. International Multidisciplinary Journal for Research & Development, 12(10), 258–264. Retrieved from https://ijmrd.in/index.php/imjrd/article/view/3853